跳至主要内容
临床试验/NCT00952419
NCT00952419已完成2 期

Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years

Sanofi Pasteur, a Sanofi Company20 个研究点 分布在 1 个国家目标入组 474 人开始时间: 2009年8月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
474
试验地点
20
主要终点
Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years

研究概览

简要总结

The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children.

Primary Objectives:

  • To describe the immunogenicity of the candidate vaccines after each injection.
  • To describe the safety of the candidate vaccines after each injection.

详细描述

Participants will receive two injections of their randomized vaccine on Day 0 and Day 21, respectively.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Months 至 9 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years

时间窗: Pre-vaccination (Day 0) and Day 21 post-vaccination

Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.

Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months

时间窗: Pre-vaccination (Day 0) and 21 days post-vaccination

Pre- and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.

Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months

时间窗: Pre-vaccination (Day 0) and 21 days post-vaccination

Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.

Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years

时间窗: Pre-vaccination (Day 0) and Day 21 post-vaccination

Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.

Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 3 to 9 Years

时间窗: Days 0 to 7 post vaccination

Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering.

Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 6 to 23 Months

时间窗: Days 0 to 7 post-vaccination

Solicited Injection Site Reactions: Tenderness, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, irritability.

Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Following Vaccination - Age 24 to 35 Months

时间窗: Days 0 to 7 post-vaccination

Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering.

Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months

时间窗: Pre-vaccination (Day 0) and Day 21 post-vaccination

Seroprotection: Antibody titer of ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.

Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 3 to 9 Years

时间窗: Pre-vaccination (Day 0) and 21 days post-vaccination

Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验